The role of intravenous iron in anemia management and transfusion avoidance. （打开新窗口）

Auerbach M, Goodnough LT, Picard D, Maniatis A.

来源‎: Transfusion 2008;48(5):988-1000.

检索‎: PubMed 18346021

DOI码‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 （打开新窗口）

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. （打开新窗口）

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

来源‎: BJU Int 2011;108(10):1582-7.

检索‎: PubMed 21443653

DOI码‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 （打开新窗口）

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. （打开新窗口）

Lepor H, Lipkin M, Slova D.

来源‎: Urology 2010;75(6):1424-8.

检索‎: PubMed 20513505

DOI码‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 （打开新窗口）

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. （打开新窗口）

Nieder AM, Rosenblum N, Lepor H.

来源‎: Urology 2001;57(4):737-41.

检索‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 （打开新窗口）